Zobrazeno 1 - 10
of 48
pro vyhledávání: '"David F. Claxton"'
Autor:
Christopher J. Pizzola, Joseph Cioccio, Kevin L. Rakszawski, Myles Nickolich, W. Christopher Ehmann, Witold B. Rybka, Baldeep Wirk, Seema Naik, Hong Zheng, Brooke Silar, Hiroko Shike, Shouhao Zhou, Shin Mineishi, Kentaro Minagawa, David F. Claxton
Publikováno v:
Bone Marrow Transplantation. 57:1743-1745
Autor:
Andrei V. Khokhlatchev, Arati Sharma, Tye G. Deering, Jeremy J. P. Shaw, Pedro Costa‐Pinheiro, Upendarrao Golla, Charyguly Annageldiyev, Myles C. Cabot, Mark R. Conaway, Su‐Fern Tan, Johnson Ung, David J. Feith, Thomas P. Loughran, David F. Claxton, Todd E. Fox, Mark Kester
Publikováno v:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 36(10)
Despite several new therapeutic options for acute myeloid leukemia (AML), disease relapse remains a significant challenge. We have previously demonstrated that augmenting ceramides can counter various drug-resistance mechanisms, leading to enhanced c
Autor:
Shin Mineishi, Pan Zheng, Robert F. Paulson, W. Christopher Ehmann, Hiroko Shike, Bei Jia, K. Sandeep Prabhu, Todd D. Schell, Yi Zhang, Chenchen Zhao, Michael G. Bayerl, Hong Zheng, David F. Claxton, Leonard D. Shultz
Publikováno v:
J Leukoc Biol
The prognosis for acute myeloid leukemia (AML) relapse post allogeneic hematopoietic stem cell transplantation (alloSCT) is dismal. Novel effective treatment is urgently needed. Clinical benefit of alloSCT greatly relies on the graft-versus-leukemia
Autor:
Fenghua Qian, Brooke E. Arner, Kathleen M. Kelly, Charyguly Annageldiyev, Arati Sharma, David F. Claxton, Robert F. Paulson, K. Sandeep Prabhu
Publikováno v:
FASEB J
Interleukin-4 (IL-4) is a signature cytokine pivotal in Type 2 helper T cell (Th2) immune response, particularly in allergy and hypersensitivity. Interestingly, IL-4 increases endogenous levels of prostaglandin D(2) (PGD(2)) and its metabolites, Δ(1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e273f74e5287cb08661cbb150b3b620
https://europepmc.org/articles/PMC9994642/
https://europepmc.org/articles/PMC9994642/
Autor:
Johnson Ung, Su-Fern Tan, Todd E. Fox, Jeremy J.P. Shaw, Luke R. Vass, Pedro Costa-Pinheiro, Francine E. Garrett-Bakelman, Michael K. Keng, Arati Sharma, David F. Claxton, Ross L. Levine, Martin S. Tallman, Myles C. Cabot, Mark Kester, David J. Feith, Thomas P. Loughran
Publikováno v:
Blood reviews. 55
Acute myeloid leukemia (AML) is an aggressive, heterogenous malignancy characterized by clonal expansion of bone marrow-derived myeloid progenitor cells. While our current understanding of the molecular and genomic landscape of AML has evolved dramat
Publikováno v:
Stem cell reviews and reports. 18(4)
The stem cells of acute myeloid leukemia (AML) are the malignancy initiating cells whose survival ultimately drives growth of these lethal diseases. Here we review leukemia stem cell (LSC) biology, particularly as it relates to the very heterogeneous
Autor:
R.L. Bayer, Jerald P. Radich, Maria Brown, M. Lynn Savoie, Bruno C. Medeiros, Harry P. Erba, John M. Pagel, Selina M. Luger, Stephen A. Strickland, Sanjay R. Mohan, Guillermo Garcia-Manero, Dennis L. Confer, David A. Rizzieri, Stephen R. Spellman, Richard Stone, Geoffrey L. Uy, David F. Claxton, Mark R. Litzow, Min Fang, Frederick R. Appelbaum, Megan Othus, Mikkael A. Sekeres, Jeffrey Chell, Bayard L. Powell, James Essell, Guido Marcucci, Anna Moseley, Richard A. Larson, Tara L. Lin
Publikováno v:
JCO Oncol Pract
PURPOSE: Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone. Ho
Autor:
Jeff Sivik, Chenchen Zhao, Natthapol Songdej, Todd D. Schell, Witold B. Rybka, David F. Claxton, Seema Naik, Hong Zheng, Ming Wang, W. Christopher Ehmann, Bei Jia, Raymond J. Hohl, Hui Zeng, Shin Mineishi
Publikováno v:
British Journal of Haematology
Summary Decitabine is a DNA‐hypomethylating agent that has been widely applied for the treatment of acute myeloid leukaemia (AML) patients who are elderly or unfit for intensive therapy. Although effective, the complete response rate to decitabine
Autor:
Charyguly Annageldiyev, Nicole R. Keasey, Emily Sullivan, Paul T. Toran, Hong Gang Wang, Regina M. Ondrasik, Su Fern Tan, Andrea L. Cote, Tye G. Deering, Todd E. Fox, David J. Feith, Brian M. Barth, Timothy J Brown, Stephan T. Stern, Mark Kester, David F. Claxton, Thomas P. Loughran, Vasiliki Papakotsi, Arati Sharma, Ross L. Levine, David B. Needle, Junjia Zhu, Sriram S. Shanmugavelandy, Aaron D. Viny, Viola Devine, Weiyuan Wang, Jason Liao
Publikováno v:
Blood Advances. 3:2598-2603
Key Points Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.
Autor:
Pau Montesinos, Farhad Ravandi, Martha Arellano, Karen Seiter, Ellin Berman, Jessica K. Altman, Lori J. Maness, Donald P. Quick, Parameswaran Venugopal, Judy H. Chiao, Scott R. Solomon, Rakesh Gaur, Mikkael A. Sekeres, Maria R. Baer, Marc Buyse, Aleksandra Butrym, David A. Rizzieri, Stephen A. Strickland, Stuart L. Goldberg, Tapan M. Kadia, Marc Gautier, David F. Claxton, Gary J. Schiller, Gianluca Gaidano, Kebede H. Begna, Selina M. Luger, Hagop M. Kantarjian, Xavier Thomas
Publikováno v:
Cancer
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alt